Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 308

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial

Václavík, Jan, Sedlák, Richard, Plachý, Martin, Navrátil, Karel, Plášek, Jiří, Jarkovský, Jiří, Václavík, Tomáš, Husár, Roman, Kociánová, Eva, Táborský, Miloš·2011·Hypertension
DOI 10.1161/hypertensionaha.111.169961
Open this paper in CoChat — free account

Abstract

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was −5.4 mm Hg (95%CI −10.0; −0.8) for systolic BP ( P =0.024) and −1.0 mm Hg (95% CI −4.0; 2.0) for diastolic BP ( P =0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of −8.6, −6.6, and −6.5 mm Hg; P =0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (−3.0, −1.0, and −2.5 mm Hg; P =0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.111.169961

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 308

Metadata

Authors
Václavík, J., Sedlák, R., Plachý, M., Navrátil, K., Plášek, J., Jarkovský, J., Václavík, T., Husár, R., Kociánová, E., & Táborský, M.
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-06
Volume
57
Issue
6
Pages
1069-1075
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
DOI
10.1161/hypertensionaha.111.169961
OpenAlex
W2150734413
Cited by
308
References
5
FWCI
27.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1161/hypertensionaha.111.169961
The paper
Václavík, J., Sedlák, R., Plachý, M., Navrátil, K., Plášek, J., Jarkovský, J., Václavík, T., Husár, R., Kociánová, E., & Táborský, M. (2011). Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension. https://doi.org/10.1161/hypertensionaha.111.169961

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.